The ADAPT Trial: Adapting Evidence-Based Obesity Interventions in Community Settings
Vanderbilt University Medical Center · NCT06546696
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 6–12 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 750
- US sites recruiting
- 1
- Study start
- October 23, 2024
- Record last updated
- December 11, 2025
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
Evidence-based obesity treatment is inaccessible to most children in the United States. This lack of access is a source of health inequity, whereby children from rural and minority communities, who have the highest rates of childhood obesity, are also the least likely to receive an evidence-based intervention. Developing strategies to improve access to evidence-based obesity interventions could reduce health disparities by improving reach to these underserved communities. The premise of this study is that using a systematic framework to adapt a community-based behavioral intervention for childhood obesity that accounts for individual, family, and community factors will increase reach and effectiveness among low-income, minority, and rural populations. COACH is a multi-level obesity intervention that supports 1) the individual child through developmentally appropriate health behavior curriculum, 2) the family by directly addressing parent weight loss and engaging parents as agents of change for their children, and 3) the community by building the capacity of local community centers to offer parent-child programming. The investigators propose testing the process of adapting COACH in a cluster-randomized trial.
Being studied: Competency Based Approaches to Community Health (COACH)
Conditions: Childhood Obesity
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Child with an age ≥ 6 years and \< 12 years
- Child body mass index ≥95th percentile for age and sex on standardized CDC growth curves
- Index parent/legal guardian with an age ≥18 years
- Parent and child speak English or Spanish
- Family resides within or frequently visit selected zip codes within Middle TN surrounding the partnering community centers;
- Have parental commitment to participate in a 6-month study;
- Have the ability to view online trainings
- Complete baseline data collection, including parent and child height and weight and at least 90% of baseline survey items.
Exclusion Criteria
- Participant child has been diagnosed with Down Syndrome, Autism, or any other developmental disorders that impact metabolism or behaviors that would preclude participation in group physical activity settings;
- Either the participant caregiver or child is unable to participate in light to moderate physical activity;
- Participant caregiver has a serious mental or neurologic illness that impairs ability to consent/participate.
Recruiting US locations
Vanderbilt University Medical Center
Nashville, TN 37212
Site contact: William J Heerman, MD, MPH · 615-322-7080 · Bill.Heerman@vumc.org
Study contacts (from the official record)
- William J Heerman, MD, MPH · 615-322-7080 · Bill.Heerman@vumc.org
- Laura Adams, RD, MBA · 615-875-7298 · Laura.E.Adams@vumc.org
Similar studies in Tennessee
All weight loss studies in Tennessee →- RecruitingHealthy volunteersPhase 3
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- Location
- Nashville, TN + 55 other US sites
- Eligibility basics
- Ages 18–79
- RecruitingPhase 2
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
AbbVie
- Location
- Bristol, TN + 58 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes
Novo Nordisk A/S
- Location
- Memphis, TN + 13 other US sites
- Eligibility basics
- Ages 10–18
- RecruitingPhase 1
Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events
Novo Nordisk A/S
- Location
- Bristol, TN + 9 other US sites
- Eligibility basics
- Ages 18+